Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.

  title={Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.},
  author={Izidore S. Lossos and Debra K. Czerwinski and Ash A. Alizadeh and Mark A. Wechser and Robert Tibshirani and David Botstein and Ronald Levy},
  journal={The New England journal of medicine},
  volume={350 18},
BACKGROUND Several gene-expression signatures can be used to predict the prognosis in diffuse large-B-cell lymphoma, but the lack of practical tests for a genome-scale analysis has restricted the use of this method. METHODS We studied 36 genes whose expression had been reported to predict survival in diffuse large-B-cell lymphoma. We measured the expression of each of these genes in independent samples of lymphoma from 66 patients by quantitative real-time polymerase-chain-reaction analyses… 

Figures and Tables from this paper

Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.

It is concluded that the measurement of a single gene expressed by tumor cells (LMO2) and a single genes expressed by the immune microenvironment (TNFRSF9) powerfully predicts overall survival in patients with DLBCL.

Prediction of survival of diffuse large B‐cell lymphoma patients via the expression of three inflammatory genes

A three‐gene model is sufficient to predict survival of DLBCL patients via measuring the concentration of three inflammatory cytokines in peripheral blood through multivariate Cox regression based on the expression of these three genes.

Microarray gene expression data with linked survival phenotypes: diffuse large-B-cell lymphoma revisited.

This paper argues for the utility of penalized approaches, in particular least angle regression-least absolute shrinkage and selection operator (Efron et al., 2004), and develops residual-based approximations that eliminate this burden yet perform similarly.

Survival prediction of diffuse large-B-cell lymphoma based on both clinical and gene expression information

An integrated clinicogenomic modeling approach is described that combines gene expression profiles and the clinically based International Prognostic Index (IPI) for personalized prediction in disease outcome, delivering predictions more accurate than those achieved by using either clinical data or molecular predictors alone.

Microarray Gene Expression Data with Linked Survival Phenotypes: Diffuse Large-B-Cell Lymphoma Revisited

The intent of this paper is to reevaluate microarray-based prognostic assessments of DLBCL, and extend the statistical methodology that has been used in this context, and argue for the utility of penalized approaches, in particular LARS-Lasso.

Predicting the survival time for diffuse large B-cell lymphoma using microarray data

Ridge regression method had higher capacity than other dimension reduction methods for the prediction of survival time in patients with DLBCL, and a combination of statistical methods and microarray data could help to detect influential genes in survival.

Prognostic efficacy of the human B-cell lymphoma prognostic genes in predicting disease-free survival (DFS) in the canine counterpart

The multivariate Cox proportional-hazard analysis confirmed CCND1 and BIRCS5 as prognostic genes for canine B-cell lymphoma and confirmedCCND1 as important gene that can be used as a potential predictor in this tumor type.

Diffuse large B cell lymphoma: from gene expression profiling to prediction of outcome.

  • I. Lossos
  • Biology
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2008

Incremental value in outcome prediction with gene expression-based signatures in diffuse large B-cell lymphoma.

These gene-based signatures are inferior to clinical factors and provide little added value in risk assessment, and to develop highly discriminating risk prediction models, needs to use appropriate approaches and consider more than gene expression.



The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

DNA microarrays can be used to formulate a molecular predictor of survival after chemotherapy for diffuse large-B-cell lymphoma and this gene-based predictor and the international prognostic index were independent prognostic indicators.

Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.

High BCL-6 mRNA expression should be considered a new favorable prognostic factor in DLBCL and should be used in the stratification and the design of risk-adjusted therapies for patients withDLBCL.

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

Genes implicated in DLBCL outcome included some that regulate responses to B-cell–receptor signaling, critical serine/threonine phosphorylation pathways and apoptosis, and identify rational targets for intervention.

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

The ability of this gene expression-based predictor to classify DLBCLs into biologically and clinically distinct subgroups irrespective of the method used to measure gene expression is demonstrated.

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.

Sequential addition of bcl-2 expression and GC phenotype into the IPI significantly improves risk stratification in DLBCL and alternative treatment strategies should be considered in future trials.

Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.

  • M. KramerJ. Hermans P. Kluin
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
PURPOSE We studied the prognostic significance of bcl2 and p53 protein expression in relation to clinical and pathologic characteristics in patients with diffuse large B-cell lymphoma (LCL).

Prognostic clinicopathologic factors, including immunologic expression in diffuse large B‐cell lymphomas

Clinical factors appeared to be more important than biologic parameters in determining the prognosis of diffuse large B‐cell lymphomas and the expression of p53 and bcl‐6 proteins may be useful prognostic indicators in DLBCL.

Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.

Multivariate analysis incorporating prognostic factors from the international prognostic index demonstrated that p53 mutations had independent effects on the rates of complete remission and survival.

CD44 expression predicts disease outcome in localized large B cell lymphoma

CD44 is identified as a biological prognosticator, which can be used to ‘fine-tune’ the IPI for nodal DLCL, and incorporation of CD44s in theIPI parameter ‘stage’, increased the prognostic value of this parameter in nodalDLCL.

HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma.

Patients with DLBCL expressing high levels of HGAL mRNA demonstrate significantly longer overall survival than do patients with low HGAL expression, independent of the clinical international prognostic index.